| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...624405W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0024405 |
| P8608 | Fatcat ID | release_twcuml7aznbfre7i2ikf5a3lye |
| P932 | PMC publication ID | 3170300 |
| P698 | PubMed publication ID | 21931707 |
| P5875 | ResearchGate publication ID | 51655731 |
| P50 | author | Alan C. Perkins | Q37838612 |
| P2093 | author name string | Yong Li | |
| Li Wang | |||
| John H Kearsley | |||
| Hongmin Chen | |||
| Julia Beretov | |||
| Mohammad H Pourgholami | |||
| Jingli Hao | |||
| Hongtu Chao | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide | Q46871169 | ||
| Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts | Q46934619 | ||
| A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats | Q48315228 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope | Q72890618 | ||
| Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels | Q74619168 | ||
| Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance | Q79972618 | ||
| Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma | Q80565368 | ||
| Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer | Q83774542 | ||
| Expression of aberrantly glycosylated Mucin‐1 in ovarian cancer | Q85212499 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| PARP-1, a determinant of cell survival in response to DNA damage | Q28182341 | ||
| MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma | Q28259350 | ||
| Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation | Q28266311 | ||
| Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer | Q28288802 | ||
| Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis | Q28292299 | ||
| Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase | Q28302692 | ||
| Rise and fall of an anti-MUC1 specific antibody | Q28743508 | ||
| Constitutive and antibody-induced internalization of prostate-specific membrane antigen. | Q32015731 | ||
| A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer | Q34254918 | ||
| The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature | Q34273106 | ||
| Recent advances in the treatment of epithelial ovarian cancer | Q34481727 | ||
| Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. | Q34552660 | ||
| A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship | Q34690734 | ||
| Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease | Q34826559 | ||
| Microtubules, microtubule-interfering agents and apoptosis. | Q35219575 | ||
| Drug delivery and transport to solid tumors | Q35563687 | ||
| Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization | Q35753569 | ||
| Ovarian cancer metastasis: integrating insights from disparate model organisms | Q36111930 | ||
| Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside | Q36581822 | ||
| MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate | Q36695246 | ||
| Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways | Q36752265 | ||
| Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma | Q37169042 | ||
| Beyond chemotherapy: targeted therapies in ovarian cancer | Q37399899 | ||
| Promising tumor-associated antigens for future prostate cancer therapy. | Q37523602 | ||
| Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer | Q39632081 | ||
| Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer | Q39695801 | ||
| Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro | Q39910773 | ||
| High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). | Q40095351 | ||
| Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice | Q40301376 | ||
| In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595. | Q40388290 | ||
| An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines | Q40407981 | ||
| Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters | Q40408539 | ||
| Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates | Q40508166 | ||
| C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas | Q42383836 | ||
| A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study | Q44315213 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| docetaxel | Q420436 | ||
| monoclonal antibody | Q422248 | ||
| ovarian cancer | Q172341 | ||
| P304 | page(s) | e24405 | |
| P577 | publication date | 2011-09-09 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model | |
| P478 | volume | 6 |
| Q47104633 | A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer |
| Q64917760 | A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model. |
| Q26748666 | Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options |
| Q35116847 | CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance |
| Q57027548 | Chemotherapeutic Efficacy of Implantable Antineoplastic-Treatment Protocols in an Optimal Mouse Model for Human Ovarian Carcinoma Cell Targeting |
| Q33741303 | Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells. |
| Q37657753 | Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach |
| Q28482047 | In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147 |
| Q37636939 | MUC1 and metastatic cancer: expression, function and therapeutic targeting |
| Q90119618 | Monoclonal anti‑MUC1 antibody with novel octahydropyrazino[2,1‑a:5,4‑a']diisoquinoline derivative as a potential multi‑targeted strategy in MCF‑7 breast cancer cells |
| Q35517037 | Nanoparticle formulation of ormeloxifene for pancreatic cancer |
| Q36489491 | Polydopamine-enabled surface functionalization of gold nanorods for cancer cell-targeted imaging and photothermal therapy |
| Q38142315 | Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy |
| Q37687556 | Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. |
| Q36621615 | The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells |
| Q38100999 | The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. |
Search more.